235 related articles for article (PubMed ID: 30338693)
21. [Diagnosis and Treatment of Primary Biliary Cholangitis].
Kim KA
Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
[TBL] [Abstract][Full Text] [Related]
22. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Yokoda RT; Carey EJ
Am J Gastroenterol; 2019 Oct; 114(10):1593-1605. PubMed ID: 31169523
[TBL] [Abstract][Full Text] [Related]
23. Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?
Wetten A; Jones DEJ; Dyson JK
Expert Opin Pharmacother; 2021 Oct; 22(15):1949-1953. PubMed ID: 34121570
[No Abstract] [Full Text] [Related]
24. Primary biliary cholangitis: Old and novel therapy.
Floreani A; Mangini C
Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
[TBL] [Abstract][Full Text] [Related]
25. An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis.
Burman BE; Jhaveri MA; Kowdley KV
Clin Liver Dis; 2017 Nov; 21(4):709-723. PubMed ID: 28987258
[TBL] [Abstract][Full Text] [Related]
26. Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation.
Quigley G; Al Ani M; Nadir A
Dig Dis Sci; 2018 Feb; 63(2):529-532. PubMed ID: 29305737
[No Abstract] [Full Text] [Related]
27. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
Zhang H; Li S; Feng Y; Zhang Q; Xie B
Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
[TBL] [Abstract][Full Text] [Related]
29. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
30. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
Silveira MG; Lindor KD
Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
[TBL] [Abstract][Full Text] [Related]
31. [In process].
Christ MM
Med Monatsschr Pharm; 2017 Mar; 40(3):132-3. PubMed ID: 29952488
[No Abstract] [Full Text] [Related]
32. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
33. Finding the cure for primary biliary cholangitis - Still waiting.
Tanaka A; Gershwin ME
Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
[TBL] [Abstract][Full Text] [Related]
34. [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].
Hohenester S; Beuers U
Internist (Berl); 2017 Aug; 58(8):805-825. PubMed ID: 28721532
[TBL] [Abstract][Full Text] [Related]
35. [Autoimmune mediated cholestatic liver diseases].
Mayer LS; Käser R; Böttler T
Dtsch Med Wochenschr; 2020 Mar; 145(5):296-305. PubMed ID: 32120404
[TBL] [Abstract][Full Text] [Related]
36. Emerging therapies for PBC.
Chascsa DMH; Lindor KD
J Gastroenterol; 2020 Mar; 55(3):261-272. PubMed ID: 31970467
[TBL] [Abstract][Full Text] [Related]
37. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
Front Immunol; 2022; 13():940688. PubMed ID: 35880178
[TBL] [Abstract][Full Text] [Related]
39. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
Abbas N; Culver EL; Thorburn D; Halliday N; Crothers H; Dyson JK; Phaw A; Aspinall R; Khakoo SI; Kallis Y; Smith B; Patanwala I; McCune A; Chimakurthi CR; Hegade V; Orrell M; Jones R; Mells G; Thain C; Thain RM; Jones D; Hirschfield G; Trivedi PJ
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1561-1570.e13. PubMed ID: 35961518
[TBL] [Abstract][Full Text] [Related]
40. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
